Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • pharma-news
    • Piramal Group to...

    Piramal Group to infuse Rs 500 crore in pharma operations in Telangana

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2020-01-23T10:15:21+05:30  |  Updated On 23 Jan 2020 10:15 AM IST
    Piramal Group to infuse Rs 500 crore in pharma operations in Telangana

    Hyderabad: Healthcare major Piramal Group has agreed to invest Rs 500 crore over the next three years in Telangana for setting up new facilities and warehousing expansion, an official release said on Wednesday.

    Minister for Industries and IT KT Rama Rao who is currently in Davos attending the annual meeting of World Economic Forum met Piramal Group chairman Ajay Piramal on Tuesday, it said.

    "After a series of deliberations at the Telangana Pavilion in Davos, the Piramal Group has agreed to invest an amount of Rs 500 crore over the next three years in the state. The proposed investment is expected to increase production capacities with the creation of new manufacturing blocks, warehouse expansion, and Utility augmentation etc," it said.

    KTR welcomed the decision of Piramal Pharma to expand their operations in the state and assured that the government will provide necessary assistance to the group, according to the release.

    Piramal is also keen on adding capacities through acquisitions in and around Hyderabad, Telangana region with an aim to support active pharmaceutical ingredients (API) manufacturing, run CSR activities in the areas of Primary Healthcare (Piramal Swasthya)and safe drinking water (Piramal Sarvajal) in and around Digwal village in the state, it said.

    In addition, the Piramal Group plans to shift their plant from other states to a new location in Hyderabad in order to take advantage of the ease of business without roadblocks offered by the Telangana government.

    "This proposed expansion in the healthcare sector in Hyderabad will employ over 500 people at an additional revenue of up to Rs 500 crore. It shall be among the best facilities globally engaged in manufacturing life-saving medicines. The Piramal leadership team plans to visit the new site early next month," it added.

    Piramal Pharma presently has a manufacturing facility in Telangana, a GMP API manufacturing facility approved by various regulatory agencies across the globe including USFDA and EU.

    Presently, Piramal employs close to 1,400 people including staff and contract workmen employed at the site with plans to add another 600 jobs by FY23 to support the expansion.

    In addition, close to 300 people will be indirectly engaged with the facility on a regular basis through various service contracts, the release added.

    Also Read: Piramal Divests Its Healthcare Analytics Business For 950 Million USD

    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok